ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY

During the analysis of valdoxan (agomelatine) effectiveness in the treatment of depressive disorders (50 patients) clinical predictors of the most complete response to the point of remission are marked. Among patients who completed the study (40 patients), 36 were responders (90 %). The remission wa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	O. V. Petrunko
Formato:	article
Lenguaje:	RU
Publicado:	Scientific Сentre for Family Health and Human Reproduction Problems 2014
Materias:	depressive disorder antidepressant therapy remission primary response valdoxan Science Q
Acceso en línea:	https://doaj.org/article/644486a287204fc78e56a97c52dc1114
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:644486a287204fc78e56a97c52dc1114
record_format	dspace
spelling	oai:doaj.org-article:644486a287204fc78e56a97c52dc11142021-11-23T06:14:31ZACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY2541-94202587-9596https://doaj.org/article/644486a287204fc78e56a97c52dc11142014-11-01T00:00:00Zhttps://www.actabiomedica.ru/jour/article/view/1830https://doaj.org/toc/2541-9420https://doaj.org/toc/2587-9596During the analysis of valdoxan (agomelatine) effectiveness in the treatment of depressive disorders (50 patients) clinical predictors of the most complete response to the point of remission are marked. Among patients who completed the study (40 patients), 36 were responders (90 %). The remission was seen in 27 patients of 40. Primary response after 1-2 weeks of therapy was defined as a prognostic factor of remission.O. V. PetrunkoScientific Сentre for Family Health and Human Reproduction Problemsarticledepressive disorderantidepressant therapyremissionprimary responsevaldoxanScienceQRUActa Biomedica Scientifica, Vol 0, Iss 6, Pp 29-33 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	depressive disorder antidepressant therapy remission primary response valdoxan Science Q
spellingShingle	depressive disorder antidepressant therapy remission primary response valdoxan Science Q O. V. Petrunko ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY
description	During the analysis of valdoxan (agomelatine) effectiveness in the treatment of depressive disorders (50 patients) clinical predictors of the most complete response to the point of remission are marked. Among patients who completed the study (40 patients), 36 were responders (90 %). The remission was seen in 27 patients of 40. Primary response after 1-2 weeks of therapy was defined as a prognostic factor of remission.
format	article
author	O. V. Petrunko
author_facet	O. V. Petrunko
author_sort	O. V. Petrunko
title	ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY
title_short	ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY
title_full	ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY
title_fullStr	ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY
title_full_unstemmed	ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY
title_sort	achievement of remission as a modern purpose of antidepressant therapy
publisher	Scientific Сentre for Family Health and Human Reproduction Problems
publishDate	2014
url	https://doaj.org/article/644486a287204fc78e56a97c52dc1114
work_keys_str_mv	AT ovpetrunko achievementofremissionasamodernpurposeofantidepressanttherapy
_version_	1718417072394862592

ACHIEVEMENT OF REMISSION AS A MODERN PURPOSE OF ANTIDEPRESSANT THERAPY

Ejemplares similares